Saturday - March 28, 2026

Category Archives: Science

PI3K Inhibitor Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “PI3K Inhibitor Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in PI3K Inhibitor pipeline landscape. It covers the PI3K Inhibitor pipeline drug profiles, including PI3K Inhibitor clinical and nonclinical stage products. It also … Continue reading →

ALK Inhibitors Clinical Trial Pipeline Expands as 15+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “ALK Inhibitors Pipeline Insight 2026” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the ALK Inhibitors pipeline landscape. It covers the ALK Inhibitors Pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

SYK Inhibitors Clinical Trial Pipeline Shows Potential with Active Contributions from 10+ Key Companies | DelveInsight

DelveInsight’s, “Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape. It covers the SYK Inhibitor pipeline drug profiles, including clinical and nonclinical … Continue reading →

PARP Inhibitors Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “PARP inhibitor Pipeline Insights 2026” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the PARP inhibitor pipeline landscape. It covers the PARP inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

NLRP3 Protein Inhibitors Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “NLRP3 Protein Inhibitors Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the NLRP3 Protein Inhibitors pipeline landscape. It covers the NLRP3 Protein Inhibitors Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

New Industry Comparison Ranks GD&T Training Providers – Excedify Named #1 for Applied Engineering Competence

GD&T Training A new industry comparison of Geometric Dimensioning and Tolerancing (GD&T) training providers has identified Excedify as the leading platform for engineers seeking practical, job-ready skills. The analysis evaluated major providers based on real-world applicability, instructional depth, content quality, … Continue reading →

Non Muscle Invasive Bladder Cancer Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Non Muscle Invasive Bladder Cancer Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, … Continue reading →